Published in Clin Exp Immunol on June 01, 2007
Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43
Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood (2008) 3.18
'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection. Nat Immunol (2010) 2.57
Natural killer cell education and tolerance. Cell (2010) 2.02
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant (2010) 1.72
KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res (2009) 1.50
Improving the outcome of leukemia by natural killer cell-based immunotherapeutic strategies. Front Immunol (2014) 1.10
Donor killer immunoglobulin-like receptor genes and reactivation of cytomegalovirus after HLA-matched hematopoietic stem-cell transplantation: HLA-C allotype is an essential cofactor. Front Immunol (2013) 1.06
Mouse NK cell-mediated rejection of bone marrow allografts exhibits patterns consistent with Ly49 subset licensing. Blood (2011) 1.01
Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies. Leukemia (2009) 0.97
Human diversity of killer cell immunoglobulin-like receptors and disease. Korean J Hematol (2011) 0.97
Decreased infections in recipients of unrelated donor hematopoietic cell transplantation from donors with an activating KIR genotype. Biol Blood Marrow Transplant (2010) 0.96
Re-educating natural killer cells. J Exp Med (2010) 0.93
The role of KIR genes and ligands in leukemia surveillance. Front Immunol (2013) 0.91
Natural killer cells: tolerance to self and innate immunity to viral infection and malignancy. Biol Blood Marrow Transplant (2009) 0.86
Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease. Cytotherapy (2014) 0.85
Role of HLA in Hematopoietic Stem Cell Transplantation. Bone Marrow Res (2012) 0.83
Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis. Pediatr Blood Cancer (2014) 0.80
Enhanced cytotoxic function of natural killer and CD3+CD56+ cells in cord blood after culture. Biol Blood Marrow Transplant (2014) 0.77
HLA-C KIR-Ligands Determine the Impact of Anti-Thymocyte Globulin (ATG) on Graft versus Host and Graft versus Leukemia Effects Following Hematopoietic Stem Cell Transplantation. Biomedicines (2017) 0.76
Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med (1999) 22.81
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 12.75
Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature (1986) 9.73
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood (2001) 4.65
Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood (2003) 3.88
Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood (2005) 3.65
Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood (1999) 3.53
Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med (1986) 3.22
The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant (2006) 2.93
KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant (2006) 2.10
Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood (2002) 2.03
Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood (2002) 2.03
Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia (2003) 1.96
NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood (2005) 1.78
Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Blood (2003) 1.70
The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood (2003) 1.70
High stem cell dose will not compensate for T cell depletion in allogeneic non-myeloablative stem cell transplantation. Bone Marrow Transplant (2002) 1.46
The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens (2004) 1.31
Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation (2006) 1.24
Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Haematol (2003) 1.15
Use of natural killer cells in hematopoetic stem cell transplantation. Bone Marrow Transplant (2005) 1.08
Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants. Eur J Haematol (2006) 1.05
Inhibitory killer Ig-like receptor genes and human leukocyte antigen class I ligands in haematopoietic stem cell transplantation. Curr Opin Immunol (2004) 1.04
Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning. Br J Haematol (2005) 1.02
Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. Blood (2004) 1.02
Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood (2000) 0.99
Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: results of a European survey. J Clin Oncol (2002) 0.98
The repertoire of HLA-Cw-specific NK cell receptors CD158 a/b (EB6 and GL183) in individuals with different HLA phenotypes. Immunology (1997) 0.97
Transplantation tolerance induced by "mega dose" CD34+ cell transplants. Exp Hematol (2000) 0.94
CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies. Exp Hematol (2005) 0.91
A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34+ cells/kg be considered the minimum threshold? Bone Marrow Transplant (2000) 0.88
Impact of transplanted CD34+ cell dose in allogeneic unmanipulated peripheral blood stem cell transplantation. Bone Marrow Transplant (2003) 0.87
Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors. Bone Marrow Transplant (2003) 0.86
HLA-identical stem cell transplantation: is there an optimal CD34 cell dose? Bone Marrow Transplant (2003) 0.84
CD34 cell dose and chronic graft-versus-host disease after human leukocyte antigen-matched sibling hematopoietic stem cell transplantation. Leuk Lymphoma (2004) 0.82
CD34 + cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Leuk Lymphoma (2005) 0.82
Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission. Biol Blood Marrow Transplant (2005) 0.80
CD34+ cell dose, conditioning regimen and prior chemotherapy: factors with significant impact on the early kinetics of donor chimerism after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant (2004) 0.79
Donor natural killer (NK1.1+) cells do not play a role in the suppression of GVHD or in the mediation of GVL reactions after DLI. Biol Blood Marrow Transplant (2001) 0.77
Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature (1985) 7.07
Human p53 gene localized to short arm of chromosome 17. Nature (1986) 4.67
Transient neurologic toxicity after hyperbaric subarachnoid anesthesia with 5% lidocaine. Anesth Analg (1993) 4.24
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut (2007) 4.21
Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells. Lancet (2000) 3.18
Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci U S A (1985) 3.15
Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell (1984) 3.05
Survival after bone marrow transplantation from cytomegalovirus seropositive sibling donors. Lancet (2001) 2.77
Detection of human cytomegalovirus in plasma of AIDS patients during acute visceral disease by DNA amplification. J Clin Microbiol (1992) 2.44
Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis (2001) 2.34
Immunologically distinct p53 molecules generated by alternative splicing. Mol Cell Biol (1986) 2.20
Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer (1999) 2.17
Deformation-mechanism map for nanocrystalline metals by molecular-dynamics simulation. Nat Mater (2003) 2.16
Molecular basis for heterogeneity of the human p53 protein. Mol Cell Biol (1986) 2.14
Inactivation of p53 gene expression by an insertion of Moloney murine leukemia virus-like DNA sequences. Mol Cell Biol (1984) 2.00
Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet (2000) 1.94
C3bi-binding protein on Candida albicans: temperature-dependent expression and relationship to human complement receptor type 3. Infect Immun (1989) 1.76
Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule. Mol Cell Biol (1985) 1.72
Induction of Fas ligand expression by HIV involves the interaction of Nef with the T cell receptor zeta chain. J Exp Med (1999) 1.63
Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea. Am J Med (1987) 1.61
CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. J Clin Pathol (2004) 1.57
FtsK-dependent and -independent pathways of Xer site-specific recombination. EMBO J (1999) 1.56
High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer (2008) 1.56
Unified nomenclature for subunits of the Saccharomyces cerevisiae proteasome regulatory particle. Trends Biochem Sci (1998) 1.55
Differential localization of HDAC4 orchestrates muscle differentiation. Nucleic Acids Res (2001) 1.49
In vitro expression of human p53 cDNA clones and characterization of the cloned human p53 gene. Mol Cell Biol (1985) 1.46
Importance of Kupffer cells for T-cell-dependent liver injury in mice. Am J Pathol (2000) 1.42
Interruption of classic CD40L-CD40 signalling but not of the novel CD40L-Mac-1 interaction limits arterial neointima formation in mice. Thromb Haemost (2014) 1.41
Biological and molecular analysis of p53 cellular-encoded tumor antigen. Adv Cancer Res (1985) 1.40
Expression of p53 in human leukemia and lymphoma. Blood (1986) 1.40
Considering changes in adjustment disorder. Hosp Community Psychiatry (1993) 1.39
Nutrition services for alcohol/substance abuse clients. Indian Health Service's tribal survey provides insight. J Am Diet Assoc (1994) 1.36
TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol (2008) 1.32
Cytokine manipulation of primitive human hematopoietic cell self-renewal. Proc Natl Acad Sci U S A (1997) 1.29
Allogeneic hematopoietic SCT for patients with autoimmune diseases. Bone Marrow Transplant (2009) 1.28
Screening for Aspergillus spp. using polymerase chain reaction of whole blood samples from patients with haematological malignancies. Br J Haematol (2001) 1.27
One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther (2012) 1.24
Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology (2000) 1.23
Ep-CAM expression in pancreatic and ampullary carcinomas: frequency and prognostic relevance. J Clin Pathol (2006) 1.23
Abelson murine leukemia virus-transformed cells that lack p53 protein synthesis express aberrant p53 mRNA species. Mol Cell Biol (1984) 1.21
Essential role of the thymus to reconstitute naive (CD45RA+) T-helper cells after human allogeneic bone marrow transplantation. Blood (1997) 1.20
Variation in antigenic determinants of p53 transformation-related protein obtained from various species. J Immunol (1983) 1.19
Bacillus Calmette-Guérin mycobacteria stimulate human blood dendritic cells. Int J Cancer (1997) 1.19
Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages. Transplantation (1990) 1.18
Noninvasive evaluation of pulmonary artery pressure during exercise by saline-enhanced Doppler echocardiography in chronic pulmonary disease. Circulation (1989) 1.18
Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer (2003) 1.16
Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia (2005) 1.16
The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. Int J Antimicrob Agents (2010) 1.15
Mammaglobin gene expression: a superior marker of breast cancer cells in peripheral blood in comparison to epidermal-growth-factor receptor and cytokeratin-19. Lab Invest (2000) 1.15
Chromosomal assignment of the murine gene encoding the transformation-related protein p53. Mol Cell Biol (1984) 1.14
Inadvertent transmission of a donor's acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. N Engl J Med (1990) 1.14
Studies on equine recurrent uveitis. II: The role of infection with Leptospira interrogans serovar pomona. Curr Eye Res (1985) 1.13
A series of infections due to Capnocytophaga spp in immunosuppressed and immunocompetent patients. Clin Microbiol Infect (2003) 1.12
Impact of GvHD on quality of life in long-term survivors of haematopoietic transplantation. Bone Marrow Transplant (2010) 1.11
cDNA cloning and expression of platelet p24/CD9. Evidence for a new family of multiple membrane-spanning proteins. J Biol Chem (1991) 1.11
In vitro studies on the activity of amphotericin B and lipid-based amphotericin B formulations against Aspergillus conidia and hyphae. Mycoses (2002) 1.08
Cyclosporin blood levels do correlate with clinical complications. Lancet (1984) 1.07
Adhesive properties of the beta 3 integrins: comparison of GP IIb-IIIa and the vitronectin receptor individually expressed in human melanoma cells. J Cell Biol (1991) 1.07
cis Acting RNA sequences control the gag-pol translation readthrough in murine leukemia virus. Virology (1991) 1.07
Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients. Transpl Infect Dis (2007) 1.06
Effects of 5-HT4 receptor stimulation on basal and electrically evoked release of acetylcholine from guinea-pig myenteric plexus. Naunyn Schmiedebergs Arch Pharmacol (1992) 1.04
MRI evaluation of thermal ablation of tumors with focused ultrasound. J Magn Reson Imaging (1998) 1.03
Molecular detection of human cytomegalovirus and determination of genotypic ganciclovir resistance in clinical specimens. Clin Infect Dis (1995) 1.02
Interferon-induced enzymes: microassays and their applications: purification and assay of (2'-5')-oligoadenylate synthetase and assay of 2'-phosphodiesterase. Methods Enzymol (1981) 1.02
Functional and structural defects in HIV type 1 nef genes derived from pediatric long-term survivors. AIDS Res Hum Retroviruses (2000) 1.02
EORTC QLQ-C30 and FACT-BMT for the measurement of quality of life in bone marrow transplant recipients: a comparison. Eur J Haematol (2000) 1.01
Characterization of prejunctional muscarinic autoreceptors in the guinea-pig trachea. Br J Pharmacol (1991) 1.01
The Cleveland Clinic experience with adrenal cortical carcinoma. J Urol (1989) 1.00
Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression. Acta Neuropathol (2000) 1.00
Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood (1996) 1.00
A natural variability in the proline-rich motif of Nef modulates HIV-1 replication in primary T cells. Curr Biol (2001) 1.00
Acid-sensitive polyethylene glycol conjugates of doxorubicin: preparation, in vitro efficacy and intracellular distribution. Bioorg Med Chem (1999) 1.00
In-vitro and in-vivo studies on the induction of neopterin biosynthesis by cytokines, alloantigens and lipopolysaccharide (LPS). Clin Exp Immunol (1988) 0.99
Prototype implementation of the integrated genomic database. Comput Biomed Res (1994) 0.99
Sensitive detection of tumour cells in effusions by combining cytology and fluorescence in situ hybridisation (FISH). Br J Cancer (2004) 0.99
Presynaptic inhibitory opioid delta- and kappa-receptors in a branch of the rabbit ileocolic artery. Eur J Pharmacol (1985) 0.99
Treatment of chronic salmonella carriers with ciprofloxacin. Eur J Clin Microbiol (1986) 0.98
Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis. Neurology (2000) 0.98
Tinea in a site of healed herpes zoster (isoloci response?) Int J Dermatol (1985) 0.97
Hematopoietic stem cells. Biomed Pharmacother (2001) 0.97
Breath acetone-aspects of normal physiology related to age and gender as determined in a PTR-MS study. J Breath Res (2009) 0.96
Rapid reappearance of large granular lymphocytes (LGL) with concomitant reconstitution of natural killer (NK) activity after human bone marrow transplantation (BMT). Br J Haematol (1987) 0.96
Esophageal cancer: determination of internal target volume for conformal radiotherapy. Radiother Oncol (2006) 0.96
Transfusion of donor-type red cells as a single preparative treatment for bone marrow transplants with major ABO incompatibility. Transfusion (1995) 0.96
Protective effect of XY99-5038 on hydrogen peroxide induced cell death in cultured retinal neurons. Life Sci (2001) 0.96